生物技术公司Onconano Medicine近日宣布，已与全球生物制药巨头吉利德科学（Gilead Sciences）签署一项研究合作协议。根据协议条款，Onconano Medicine将把其专有的On-Board™药物递送技术平台应用于吉利德科学旗下某一未公开的候选药物开发中。
这项合作旨在探索利用纳米技术增强药物靶向性与疗效的新路径。On-Board™技术以其精准递送特性著称，有望提升治疗分子在病灶部位的富集度，同时减少对健康组织的副作用。双方未透露具体财务条款及研发时间表，但表示将共同推进该候选药物的临床前研究阶段。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.